NEW YORK, August 5, 2013 /PRNewswire/ --
Today, Investors' Reports announced new research reports highlighting Seattle Genetics Inc. (NASDAQ: SGEN), Santarus, Inc. (NASDAQ: SNTS), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), and PDL BioPharma, Inc. (NASDAQ: PDLI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Seattle Genetics Inc. Research Report
On July 31, 2013, Seattle Genetics, Inc. (Seattle Genetics) reported its Q2 2013 financial results posting total revenues of $73.6 million compared to $48.8 million in Q2 2012. Revenues included ADCETRIS (brentuximab vedotin) net product sales totaling to $35.7 million. Revenues also reflected total earnings under the Company's ADCETRIS and ADC collaborations totaling $34.3 million. According to the Company, collaboration revenues increased in 2013 driven by the Company's ADCETRIS collaboration with Takeda/Millennium. Net loss for the quarter totaled $6.9 million or $0.06 per share, compared to net loss of $17.2 million or $0.15 per share in Q2 2012. Seattle Genetics now anticipates that collaboration and license agreement revenues will be in the range of $85 million to $95 million for full-year 2013. The Full Research Report on Seattle Genetics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-01/SGEN]
Santarus, Inc. Research Report
On July 23, 2013, Santarus Inc. (Santarus) announced the schedule of the release of its Q2 2013 financial results. The Company will report its earnings on August 6, 2013, after the market close. Following the release, the Company will host an investment-community conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a corporate update. A webcast replay of the call will be available on the Santarus website for 14 days, after the completion of the call. The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-01/SNTS]
BioCryst Pharmaceuticals, Inc. Research Report
On July 23, 2013, BioCryst Pharmaceuticals Inc. (BioCryst) announced the appointment of Fred E. Cohen, M.D., D.Phil., to the Company's Board of Directors. "The Board of Directors and Leadership Team of BioCryst are very pleased to have Fred join the Company's Board," said George B. Abercrombie, Chairman of the Board of BioCryst. "Fred brings a wealth of scientific knowledge and business acumen to BioCryst and has been a valuable resource to the organization for several years as both an advisor and as an investor. We look forward to his guidance and insights toward the further success of BioCryst." According to the Company, Dr. Cohen serves on the Board of Directors of Genomic Health, Quintiles Transnational and the Boards of several privately held companies. The Full Research Report on BioCryst Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-01/BCRX]
NPS Pharmaceuticals, Inc. Research Report
On July 25, 2013, NPS Pharmaceuticals, Inc. (NPS) announced the schedule of its earnings release. NPS will release its Q2 2013 financial results on August 8, 2013, at 4:30 p.m. ET. Following the release, NPS management will host a conference call and webcast at 5:00 p.m. ET. The webcast replay will be available on the NPS website through August 22, 2013, 12:00 a.m. ET. The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-01/NPSP]
PDL BioPharma, Inc. Research Report
On July 24, 2013, PDL BioPharma, Inc. (PDL BioPharma) announced the appointment of David Montez, CPA, as the Company's Controller and Chief Accounting Officer, effective immediately. "Dave brings more than 13 years of experience in overseeing accounting and financial functions across public and private companies and public accounting firms, and we are pleased to welcome him to our team," stated Peter Garcia, Vice President and Chief Financial Officer of PDL BioPharma. "We believe that his knowledge of accounting and financial reporting procedures will enhance and further strengthen our finance team." According to the Company, Mr. Montez has previously held positions at GlassPoint Solar Inc., as director of finance and corporate controller, and at Moss Adams LLP, as an audit senior manager for six years. The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-01/PDLI]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Investors' Reports